Intro

This chapter explores the application of eculizumab, a monoclonal antibody, in treating Neuromyelitis Optica Spectrum Disorders by targeting the complement system. It highlights clinical trial findings and safety considerations, particularly the importance of vaccinations to prevent meningococcal infections for patients on this therapy.